Wassim McHayleh

Articles by Wassim McHayleh

130 Sacituzumab Govitecan (SG) + Pembrolizumab (Pembro) Vs Chemotherapy (Chemo) + Pembro in Previously Untreated PD-L1–Positive Advanced Triple-Negative Breast Cancer (TNBC): Primary Results From the Randomized Phase 3 ASCENT-04/KEYNOTE-D19 Study

BySara M. Tolaney, MD, MPH,Evandro de Azambuja,Kevin Kalinsky, MD, MS,Sherene Loi, MD, PhD,Sung-Bae Kim,Clinton Yam,Bernardo Rapoport, MD,Seock-Ah Im,Barbara Pistilli,Wassim McHayleh,David W. Cescon,Junichiro Watanabe,Manuel Alejandro Lara Banuelas,Ruffo Freitas-Junior,Javier Salvador Bofill,Maryam Afshari,Dianna Gary,Lu Wang,Catherine Lai, MD, MPH,Peter Schmid, MD

135 Elacestrant in Combination With Everolimus or Abemaciclib in Patients With ER+/HER2– Locally Advanced or Metastatic Breast Cancer (mBC): Phase 2 Results From ELEVATE, an Open-Label, Umbrella Study

ByHope S. Rugo, MD,Sara M. Tolaney, MD, MPH,Nancy Chan,Giuliano Borges,Rinat Yerushalmi,Marina N. Sharifi,Wassim McHayleh,J. Thaddeus Beck,Neelima Vidula, MD,Erika P. Hamilton, MD,Kristine J. Rinn,Joyce O’Shaughnessy, MD,Giuseppe Curigliano,Javier Cortés, MD,Paula Muñoz Romero,Giulia Tonini,Alessandro Paoli,Monica Binaschi,Li Cheng,Jennifer Crozier,Tomer Wasserman,Virginia Kaklamani, MD, DSc

86 Elacestrant Combinations in Patients With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer: Update From ELEVATE, a Phase 1b/2, Open-Label, Umbrella Study

ByHope S. Rugo, MD,Sara M. Tolaney, MD, MPH,Nancy Chan,Erika P. Hamilton, MD,Marina Sharifi,Kristine Rinn,Wassim McHayleh,Rinat Yerushalmi,Neelima Vidula, MD,Joyce O’Shaughnessy, MD,Guiseppe Curigliano,Javier Cortés, MD,Paula Muñoz Romero,Bartomeu Piza Vallespir,Kathy Puyana Theall,Alessandro Paoli,Monica Binaschi,Tomer Wasserman,Virginia Kaklamani, MD, DSc

Latest Updated Articles